Physiologically relevant cell line models and cell-based in vitro assays are becoming crucial tools for screening new drug candidates before moving to expensive testing using animal model. The development of cutting-edge new technologies such as CRISPR/Cas9 and induced pluripotent stem cell (iPSC) technologies has enabled the engineering of predictive and reliable in vitro disease models which afford an inexpensive, faster, efficient, and ethically compatible alternative to using costly, animal models for preliminary drug screening. 

Make Informed Go-No-Go Decisions Early in Your Drug Development! Process! Applied StemCell (ASC), an ISO-certified service provider offers a flexible assay platform with a wide-range of functional endpoints for early-stage in vitro screening of preclinical drug candidates. We use a comprehensive cell-based test battery from which you can choose assays for efficacy, safety or target discovery that suit your therapeutic pipeline. We will provide the scientific expertise, accurate and efficient screening to help you take informed decisions about your small/ large molecules early in your drug development process to avoid costly drug attrition.      

1. In Vitro Disease Modeling Genome Editing/ Correction  (Cancer cells, iPSCs, ESCs, primary cells) iPSC Reprogramming & Differentiation 3D Cell/ iPSC Culture

2. Drug Screening Phenotypic Screening Functional Validation Cell Viability/ Toxicity Mitochondrial/ Hepatic/Cardio Toxicity Customized Assay Development

1. In Vitro Disease Modeling:

Our custom screening service is ideal for CNS, cardiovascular, metabolic, cancer, and immunotherapy drug candidates.